Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2006

View Archived Issues

Chemopreventative potential of the rexinoid bexarotene

Preclinical and clinical studies examine ocular effects of bevacizumab

Preclinical update on MLN-8054

Denileukin-mediated depletion of Tregs: an important anticancer strategy / News in Context

SUVN-501 elevates hippocampal levels of acetylcholine as a potential procognitive treatment

AdipoGenix and Unigen to develop plant-based therapeutics that target fat

Tigris studies A-007 in high-grade CIN

Isis transaction to fund drug development programs

Novartis seeks approvals for Glivec in rare cancers

FX-06 for reperfusion injury safe and well tolerated in phase I study

Affiris closes EUR 8.5 million financing round

Pfizer to acquire Rinat Neuroscience

Cardiome Pharma recaps Q4 highlights

TRO-19622: clinical candidate for motor neuron disease

Preclinical proof-of-concept for Myodur in DMD

European approval for Adartrel in RLS

Novel anti-HCV drugs reported by Merck and Istituto di Ricerche di Biologia Molecolare P. Angeletti

Recent Altana patent divulges new PDE2 inhibitors for septic shock

Recent patents describe new agents for anxiety, depression, sleep disorders, etc.

Heterotrimeric G-protein complex inhibitor BIM-46187 presented at AACR meeting

Update of Synta Pharmaceutical's STA-5326 mesylate under clinical investigation

Bone-targeted rapamycin analogue with both antitumor and antiosteolytic effects

Dasatinib shows clinical benefit in CML patients resistant to imatinib

Recombinant immunocytotoxic protein for ovarian cancer shows good preclinical profile

Preclinical data on a human conjugated monoclonal antibody developed by CuraGen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...